Tel Aviv, Israel, and Oslo, Norway, November 16, 2026
BioLineRx Ltd. and Hemispherian AS have presented new clinical and preclinical findings supporting the development of GLIX1, an investigational oral small-molecule therapy being studied for glioblastoma (GBM) and other high-grade gliomas. The findings were presented through two scientific posters at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO) 2026. The research highlights progress in an ongoing Phase 1/2a clinical study, alongside preclinical evidence of antitumor activity, brain penetration, and pharmacodynamic effects in multiple glioblastoma models. GLIX1 is being developed as a potential first-in-class TET2 activator designed to target DNA damage response mechanisms in cancer cells. The companies reported that the clinical study has advanced to its fourth dose-escalation cohort, with no significant treatment-emergent adverse events identified to date. The preclinical programme also demonstrated activity in models of temozolomide-resistant glioblastoma, an important area of investigation because resistance to standard treatment remains a major challenge in managing this aggressive brain cancer. The companies believe the combined findings strengthen the scientific rationale for further evaluating GLIX1 and its ability to reach brain tumour tissue following oral administration.
GLIX1 Phase 1/2a Study Advances to Fourth Cohort
The ongoing GLIX1-C101 Phase 1/2a study is a first-in-human, open-label, multicentre clinical trial evaluating GLIX1 as a monotherapy in patients with recurrent or progressive high-grade diffuse glioma. The study is designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity, while identifying an appropriate dose for subsequent clinical development. Its initial dose-escalation phase is followed by a planned dose-expansion phase, with the patient populations and dose levels to be determined using findings from the earlier stage. According to the companies, patient dosing has now commenced in the fourth dose-escalation cohort. No significant treatment-emergent adverse events have been observed in the study so far. These early observations are encouraging from a development perspective, but the trial remains ongoing and the available announcement does not establish the treatment’s safety profile across a larger patient population or demonstrate clinical efficacy. An important upcoming component involves window-of-opportunity cohorts, which are intended to allow researchers to examine GLIX1 exposure and biological activity directly in human brain tumour tissue. This could provide valuable information about whether orally administered GLIX1 reaches its intended target in patients.
Preclinical Studies Show Antitumor Activity and Brain Penetration
The second presentation examined GLIX1 across multiple preclinical glioblastoma models, including orthotopic cell-derived xenograft (CDX) models and a patient-derived xenograft (PDX) model resistant to temozolomide (TMZ). In the SNB19 CDX model, GLIX1 demonstrated tumour eradication and prolonged survival in the experimental model. In the U87MG CDX model, treatment produced dose-dependent tumour growth inhibition. The compound also demonstrated tumour growth inhibition in the TMZ-resistant BN2276 PDX model, while temozolomide did not show comparable activity under the reported experimental conditions. These findings are relevant because temozolomide is an established component of glioblastoma treatment, and resistance can limit its effectiveness. Additional pharmacokinetic and pharmacodynamic analyses in the orthotopic U87MG model confirmed that GLIX1 was detected in brain tissue at all tested dose levels following oral administration. Total brain exposure increased with higher doses, providing evidence of dose-related exposure in the central nervous system. The studies also reported dose-dependent increases in tumour genomic 5-hydroxymethylcytosine (5hmC), a marker associated with TET2 activity. These increases correlated with tumour growth inhibition, supporting the proposed mechanism of action. However, the findings are preclinical and cannot predict the magnitude of benefit in human patients.
TET2 Activation Supports Further Clinical Development
GLIX1 is being investigated as an oral TET2 activator targeting DNA damage response pathways. TET2 is involved in DNA demethylation processes and regulation of gene activity, making its modulation an area of interest in cancer research. The companies are evaluating whether GLIX1 can exploit this biology to produce antitumor effects in glioblastoma and potentially other solid tumours. The planned window-of-opportunity cohorts are particularly important because they may provide direct evidence of drug exposure and biological activity in human tumour samples. BioLineRx and Hemispherian expect the ongoing clinical programme to provide further information for dose selection and future development decisions. Clinical results from the Phase 1 portion are anticipated in the first half of 2027, according to the companies. Overall, the SNO 2026 presentations provide an update on GLIX1’s early clinical progress and preclinical research, particularly its brain penetration and activity in treatment-resistant experimental models. GLIX1 remains investigational, and additional clinical studies will be required to establish its safety, efficacy, and potential role in treating glioblastoma.
Source: BioLineRx, Hemispherian press release



